GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » Buildings And Improvements

Island Pharmaceuticals (ASX:ILA) Buildings And Improvements : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals Buildings And Improvements?


Island Pharmaceuticals Buildings And Improvements Historical Data

The historical data trend for Island Pharmaceuticals's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Island Pharmaceuticals Buildings And Improvements Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23
Buildings And Improvements
- - -

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Buildings And Improvements Get a 7-Day Free Trial - - - - -

Island Pharmaceuticals Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.


Island Pharmaceuticals (ASX:ILA) Business Description

Traded in Other Exchanges
N/A
Address
697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its lead asset ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases.

Island Pharmaceuticals (ASX:ILA) Headlines

No Headlines